Biotech News
Related news
ELVNEnliven Therapeutics2026-10-14 20:30 EST
Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
TEVATeva Pharmaceutical Industries2026-09-18 20:30 EST
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
FATEFate Therapeutics2026-09-25 11:00 EST
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
GSKGSK plc2026-10-23 23:00 EST
GSK presents positive data for Mo-Rez in platinum-resistant ovarian cancer
RVMDRevolution Medicines2026-10-23 11:30 EST
Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026
RVMDRevolution Medicines2026-10-20 12:00 EST
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer
GSKGSK plc2026-10-18 19:36 EST
GSK presents first global data for Ris-Rez in extensive-stage small cell lung cancer
BNTXBioNTech2026-10-13 10:45 EST
BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
REGNRegeneron Pharmaceuticals2026-10-01 15:30 EST
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
KYMRKymera2026-09-01 11:00 EST
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
BioXcel
BioXcel Therapeutics is a neuroscience and immuno-oncology company focused on using artificial intelligence to identify therapeutic candidates. Its story combines data-driven discovery with development-stage biotech execution.
Recent company news
BTAIBioXcel2026-08-28 10:00 EST
BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals
BTAIBioXcel2026-05-28 11:00 EST
BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
BTAIBioXcel2026-05-15 11:00 EST
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
BTAIBioXcel2026-04-17 11:00 EST
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
BTAIBioXcel2026-04-08 11:00 EST
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
Stock data
- Close
- 0.07 USD
- Market cap
- 36.74M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States